Jupiter Industries & Leasing Ltd has announced that its Board of Directors will convene on November 12, 2026, at 3:00 PM. The meeting, held at the company's registered office in Mumbai, will primarily focus on approving the unaudited financial results and the limited review report for the quarter and half-year ended September 30, 2026. Any other business may be discussed with the Chair's permission.

Harikanta Overseas Ltd has announced that its Board of Directors will convene on November 5, 2026. The primary agenda item is to consider and approve the unaudited standalone and consolidated financial results for the half-year ended September 30, 2026. In line with SEBI regulations, the company has also informed about the closure of the trading window for designated persons from October 1, 2026, which will reopen 48 hours after the financial results are declared.

Jatinkumar Tulsibhai Patel, Managing Director of Emrock Corporation Limited, has acquired 13,20,000 equity shares, representing 6.19% of the total paid-up capital. This acquisition was executed through the conversion of warrants into equity shares on October 30, 2026, for a total consideration of ₹1,45,20,000. Following this transaction, Mr. Patel's total shareholding, along with Persons Acting in Concert (PACs), has increased to 24.47% of the company's voting rights. The filing is made in compliance with Regulation 29(1) of SEBI (SAST) Regulations, 2011.

Jay Bharat Maruti Limited announced the outcome of its Board Meeting held on November 2, 2026. The board approved the Unaudited Standalone & Consolidated Financial Results for the Second Quarter and Half Year ended September 30, 2026, along with the Limited Review Report. Additionally, Ms. Radhika Khurana was appointed as the Company Secretary and Compliance Officer effective December 18, 2026. Mr. Mayank Varma was appointed as CEO, overseeing both tooling and auto components, and Mr. Deepak Gupta was re-designated to focus on Strategy and Diversification.

Krsnaa Diagnostics Limited announced the outcome of its Board Meeting held on November 02, 2026. The Board approved and took note of the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. A limited review report was also provided. The meeting commenced at 13:30 Hrs. (IST) and concluded at 14:45 Hrs. (IST).

Krsnaa Diagnostics' consolidated revenue grew a strong 31.5% YoY to ₹270.97 Cr (+15.0% QoQ) in Q2 FY27, but consolidated PAT of ₹24.59 Cr rose just 2.7% YoY — even though it jumped 48.6% QoQ off a weak June-quarter base (₹16.55 Cr). Standalone tells a better story: PAT of ₹25.32 Cr grew 8.9% YoY on 31.2% revenue growth, a gap of over 6 percentage points versus the consolidated PAT print that points to subsidiary-level drag (likely the retail/Rajasthan rollout entities) rather than a core-business problem. No quarter-specific Street estimate for Q2 FY27 could be found; the closest available read is full-year FY27 analyst consensus of ~15-20% PAT growth and ~₹973 Cr revenue (Univest/consensus trackers) — against that bar, H1 FY27 consolidated PAT of ₹41.14 Cr is actually down 7.5% YoY (from ₹44.47 Cr in H1 FY26) even as H1 revenue grew 27.0% YoY, meaning H2 now needs to roughly double H1's profit pace to reach the low end of full-year consensus. On management's own prior commentary (May 2026 concall), the company flagged that Rajasthan ramp-up "might cause some short-term margin fluctuations in Q1 FY27" while aiming to "maintain consolidated EBITDA margins" for the full year and see "potential for PAT growth in FY27 as Rajasthan scales." That aim looks under pressure two quarters in: consolidated OPM compressed to ~26.25% from 28.72% a year ago (NPM fell to 8.87% from 11.39%), continuing — not reversing — the slide from Q1 FY27's 24.58% OPM that preview commentary had already called a five-quarter low. The compression sits below the EBITDA line too: finance costs nearly doubled YoY to ₹15.45 Cr (from ₹8.19 Cr) and depreciation rose 23.2% YoY to ₹29.06 Cr, both consistent with capex-funded expansion (consolidated PP&E rose to ₹848.83 Cr from ₹651.63 Cr at FY26-end, non-current borrowings broadly flat but current borrowings up to ₹156.55 Cr from ₹53.36 Cr) outrunning the operating leverage it's expected to eventually deliver. The quarter's other corporate developments — a 15.46 lakh and 16.21 lakh preferential warrant allotment to promoters (₹22.94 Cr received against warrants on the balance sheet) and an AI-radiology partnership with AZmed — are financing/strategic in nature and don't show up in this quarter's P&L; they're consistent with funding continued capacity additions rather than signalling distress. No management press release accompanying this result was available in the context to cross-check against the reported numbers, so there is no company framing to reconcile here beyond the filing's own notes. Set against the pre-print expectation that Q2 FY27 would be the quarter the retail arm (Krsnaa RPL) turns EBITDA-positive, this filing's single-segment disclosure (diagnostics is reported as one reportable segment under Ind AS 108) does not provide a retail-specific P&L to confirm or deny that milestone — it remains unverified from this document alone.

Jay Bharat Maruti's consolidated revenue came in at ₹823.42 Cr for Q2 FY27, up 41.3% YoY (₹582.65 Cr) and 31.4% QoQ (₹626.79 Cr) — a sharp acceleration in topline. Consolidated PAT attributable to owners was ₹32.01 Cr, up 73.7% YoY and 46.5% QoQ, with basic EPS at ₹2.96 against ₹1.70 a year ago. Standalone tells the same story at ₹823.42 Cr revenue and ₹31.12 Cr PAT, within 3% of consolidated since the lone joint venture is a small overlay. The margin picture is weaker than the PAT headline suggests. Operating margin (EBITDA/revenue, excluding other income) compressed to 9.07% from 10.54% a year ago and 10.04% last quarter — roughly 150bps and 97bps of give-back respectively — as cost of materials and other expenses grew faster than the 41% revenue jump, consistent with raw-material pressure not being fully passed through despite strong volumes. Net margin nonetheless rose to 3.89% from 3.16% YoY, but that expansion is not operating in nature: it is driven by the tax-rate cut (115BAA adoption dropped the effective rate to 25.1% from 36.2%) and a one-off-looking other income spike to ₹5.26 Cr (versus ₹0.18 Cr in Q1 FY27 and ₹1.04 Cr a year ago, unexplained in the filing). Adjusting PAT for the tax-rate effect alone brings YoY growth down to roughly +48% (closer to the ₹12.5 Cr increase in consolidated PBT, +47.8% YoY); stripping the other-income jump as well brings core pretax growth to around +32% — still trailing the 41% revenue gain, confirming margin compression, not tax, is the real operating story this quarter. We have no prior management guidance or concall commentary on record for this company, and a web search turned up no brokerage previews or consensus estimates for Q2 FY27 — JBML carries no visible formal street coverage, so vsGuidance and vsStreet are both unknown rather than inferred. The filing itself is a standard exchange letter with no MD&A-style commentary from management explaining the other-income line or the margin trend. Alongside the results, the board also approved a leadership reshuffle — Mayank Varma redesignated CEO over both the tooling and auto-components businesses, Deepak Gupta moved to Strategy & Diversification, and a new Company Secretary appointed effective December 18, 2026 — corporate developments concurrent with, but not tied to, this quarter's numbers. Going into H2 FY27, the questions this print sets up are whether OPM recovers toward the 10–10.5% band seen as recently as Q1 FY27, whether the ~25% effective tax rate holds (determining whether reported PAT keeps outrunning EBITDA), and whether the other-income line was a one-off or recurs.